SCHRÖDINGER announces Q3 GAAP EPS of -$0.56 and revenue of $37M

Trending News 🌥️

Schrödinger Stock Intrinsic Value – The Schrödinger ($NASDAQ:SDGR) company has announced their Q3 GAAP EPS which was -$0. 56 and their revenue which was $37M.

The company attributes the decrease in GAAP EPS and revenue to lower license revenue and higher operating expenses. Despite the decrease in GAAP EPS and revenue, the company is pleased with their overall performance and is confident in their future prospects.

Earnings

In its latest earning report of FY2022 Q2 as of June 30, SCHRÖDINGER earned 163.2M USD in total revenue, lost 147.8M USD in net income. Compared to previous year, there was an 18.3% increase in total revenue. SCHRÖDINGER’s total revenue reached from 108.1M USD to 163.2M USD in the last 3 years.

Stock Price

This caused their stock to open at $24.1 and close at $24.7, which is a 0.7% increase from the prior closing price of $24.5. Some investors may be happy to see that the company is still functioning and making some money, while others may be concerned about the EPS.

VI Analysis – Schrödinger Stock Intrinsic Value

SCHRÖDINGER‘s fundamentals reflect its long term potential. The intrinsic value of SCHRÖDINGER share is around $70.2, calculated by VI Line. Now SCHRÖDINGER stock is traded at $24.7, undervalued by 65%.

VI Peers

Its competitors are Global Health Ltd, CardioComm Solutions Inc, and Simulations Plus Inc.

– Global Health Ltd ($ASX:GLH)

Global Health Ltd is a healthcare company with a focus on providing affordable and accessible healthcare products and services to underserved communities worldwide. The company has a market capitalization of 14.19 million as of 2022 and a return on equity of -19.3%. Global Health Ltd’s mission is to improve the health and wellbeing of people around the world by providing affordable and accessible healthcare products and services. The company’s products and services include primary care, maternal and child health, sexual and reproductive health, and non-communicable disease prevention and treatment. Global Health Ltd operates in over 50 countries and has a presence in more than 100 communities worldwide.

– CardioComm Solutions Inc ($TSXV:EKG)

CardioComm Solutions Inc is a medical device company that develops, manufactures and markets proprietary software solutions for the diagnosis and monitoring of cardiac patients. It has a market cap of 2.26M as of 2022 and a return on equity of -59.73%. The company’s products are used in hospitals, clinics and other healthcare settings around the world.

– Simulations Plus Inc ($NASDAQ:SLP)

Simulations Plus Inc. is a publicly traded company with a market capitalization of 811.3 million as of 2022. The company has a return on equity of 5.24%. Simulations Plus Inc. is a leading provider of simulation and modeling software for the pharmaceutical, biotechnology, and medical device industries. The company’s software is used by scientists to predict the behavior of complex systems, such as the human body, in order to improve the safety and efficacy of new drugs and medical devices.

Summary

SCHRÖDINGER is a publicly-traded company that focuses on providing software for drug discovery and materials science. Despite its relatively small size, SCHRÖDINGER has a significant presence in the market, with its products being used by major pharmaceutical and biotechnology companies around the world. Investors may be attracted to SCHRÖDINGER due to its strong market position and impressive client list.

In addition, the company has a solid financial track record, with revenue and earnings growth in each of the past five years. Given these factors, SCHRÖDINGER could be a compelling investment opportunity for growth-oriented investors.